End-to-End Solutions Optimize Specialty Product Access and Market Entry in the US, EU and UK, Enhance Outcomes for Rare Disease Patients

Recognizing Rare Disease Day on February 28, to help raise awareness of the 7,000+ rare diseases.
· 10 min read

AscellaHealth and its subsidiary organizations recognized Rare Disease Day on February 28, an annual event to help raise awareness of the 7,000+ rare diseases that impact over 300 million people globally.

To reflect on this observance, AscellaHealth illustrates how cutting-edge, streamlined solutions for specialty and rare disease life sciences manufacturers ensure a streamlined launch to market, improve patient access to therapy, and increase adherence with custom clinical programs, resulting in optimized medication access and patient outcomes.

From pre-commercialization and market access planning to implementation and post-launch, AscellaHealth guides pharmaceutical manufacturers through the entire commercialization process, having launched, managed, and transitioned over 40 successful programs. Our end-to-end solutions ensure products are brought to market successfully by achieving optimal access, while our high-touch specialty pharmacy and patient management capabilities enable seamless fulfillment and increased compliance of specialty and rare disease pharmaceuticals.

These solutions also include clinical trial management, exclusive distribution partnerships, international specialty pharmacy fulfillment, unique financial and copay assistance solutions and high-touch patient support and HUB services such as patient intake, prior authorization support and custom clinical programs with interventions at key points in therapy.

AscellaHealth’s innovative life sciences solutions address the challenges and barriers to accessing therapies and obtaining optimal outcomes that rare disease patients face – from burdensome social and financial difficulties, which may impede a timely start to therapy, to compliance issues relating to patients being able to stay on therapy.

By choosing a single-source launch partner with in-depth specialty and rare disease expertise, manufacturers have access to integrated and customized services tailored to manage costs and meet specific needs throughout the product lifecycle and beyond.

Moreover, with exciting expansions in Europe and the United Kingdom, AscellaHealth’s first-in-class solutions can be offered to international pharmaceutical manufacturers looking to launch on a global level.

Learn more here.

Loading cookie banner...